CAMBRIDGE, Mass., February 10, 2023 /PRNewswire/ — Nona Biosciences, a wholly owned subsidiary of HBM Holdings Limited, is committed to cutting-edge technological innovation, offering a total solution from “Idea to IND” (“I to I^TM”), today announced it has entered into a collaboration agreement with Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate (ADC)-based therapies for the treatment of a variety of cancers.

Through the collaboration, Nona Biosciences will provide Mythic Therapeutics with access to its proprietary, fully human, heavy chain antibody (HCAb) only transgenic mouse platform and antibody generation services to be used as input to Mythic Therapeutics’ proprietary FateControl™ antibody engineering approach to generate the next generation, ADCs are used for a variety of cancers.

“We are excited to enter into an agreement with Mythic Therapeutics to advance innovation in next-generation biotherapeutics. We have accumulated extensive knowledge of ADC drug discovery, along with our advanced therapeutic antibody platforms, which have been validated by many partners worldwide. Mythic Therapeutics is a strong innovator in the research and development of ADCs in oncology with a strong foundation and world-class team. Our collaboration is expected to further enhance targeting capabilities and lead to advanced outcomes for unmet medical needs.” Jingsong WangMD, PhDCHairdresser from Nona Biosciences.

About HCAb

HCAb’s patented technology generates novel “heavy chain only” antibodies that are approximately half the size of a typical IgG. These antibodies carry IgG-like PK properties and Fc domain functions without the need for additional engineering or humanization. The absence of the light chain also minimizes the problem of light chain mismatch and heterodimerization. These properties enable the development of products with properties unattainable with traditional antibody platforms. In addition, HCAb-derived several novel therapeutic…